These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25656898)

  • 1. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
    Dienstmann R; Jang IS; Bot B; Friend S; Guinney J
    Cancer Discov; 2015 Feb; 5(2):118-23. PubMed ID: 25656898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 5. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
    Bruinooge SS; Sherwood S; Grubbs S; Schilsky RL
    J Oncol Pract; 2019 Nov; 15(11):575-583. PubMed ID: 31386607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The possibility of clinical sequencing in the management of cancer.
    Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
    Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of Genomic Sequencing in Pediatric CNS Tumors.
    Bavle AA; Lin FY; Parsons DW
    Oncology (Williston Park); 2016 May; 30(5):411-23. PubMed ID: 27188671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomic profiling of brain metastases: current knowledge and new frontiers.
    Neagu MR; Gill CM; Batchelor TT; Brastianos PK
    Chin Clin Oncol; 2015 Jun; 4(2):22. PubMed ID: 26112808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paul Workman: Drugging the Cancer Genome.
    Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
    [No Abstract]   [Full Text] [Related]  

  • 15. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
    Covell DG
    PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.
    Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C
    JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of cancer gene panels with OncoPaD.
    Rubio-Perez C; Deu-Pons J; Tamborero D; Lopez-Bigas N; Gonzalez-Perez A
    Genome Med; 2016 Oct; 8(1):98. PubMed ID: 27716338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 20. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.